<DOC>
	<DOC>NCT00553696</DOC>
	<brief_summary>To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.</brief_summary>
	<brief_title>Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically or cytologically confirmed diagnosis of gastric cancer Chemonaive patients Adequate organ function Patients who meet the contraindications of S1 and Cisplatin. Prior chemotherapy failure patients</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>combination</keyword>
</DOC>